Skip to main content
SpringerLink
Log in

Grundlagen der systemischen Therapie

  • Chapter
  • First Online:
Uroonkologie

  • 2860 Accesses

Zusammenfassung

In diesem Beitrag werden neue Konzepte der systemischen Therapie vorgestellt, die auf den Erkenntnissen molekularbiologischer, molekulagenetischer und immunologischer Grundlagenforschung basieren. Diese „targeted drugs“ finden bereits Anwendung in der Uroonkologie, etwa in Form zielgerichteter Hemmstoffe der Angiogenese und des PI3K/AKT-Signalweges, die in der Behandlung des fortgeschrittenen Nierenzellkarzinoms mittlerweile fest etabliert sind. Andere Therapiemodalitäten befinden sich hingegen noch im frühen Entwicklungsstadium.Die Toxizität ist neben dem Ansprechen des Tumors und dem Überleben des Patienten das wichtigste Kriterium zur Beurteilung einer Therapie. Hier werden das praktische Vorgehen bei der Chemotherapie inkl. Chemotherapieprotokollen und bei der Immuntherapie sowie das Management der Nebenwirkungen beschrieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

Literatur zu ▶ Abschn. 15.2

  • Aapro M (2005) Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin 21 (6): 885–897

    Article  CAS  PubMed  Google Scholar 

  • Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (5): 909–918

    Article  CAS  PubMed  Google Scholar 

  • Barth J, Kloke M (2003) Paravasation bei Zytostatika. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie, 4. Aufl. Springer 2003, Berlin Heidelberg New York Tokio, S 1708–1715

    Google Scholar 

  • Basser RL, Green MD (1994) Pulmonary toxicities. In: Kirkwood JM, Lotze MT, Yasko JM (eds) Current cancer therapeutics. Current Medicine, Philadelphia, pp 272–278

    Google Scholar 

  • Bellone JD (1981) Treatment of vincristin extravasation. JAMA 245: 343

    Article  CAS  PubMed  Google Scholar 

  • Billingham ME, Mason GW, Bristow MR et al. (1978) Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Pep 62: 865–872

    CAS  Google Scholar 

  • Bokemeyer C, Oechsle K, Hartmann JT, Schoffski P, Schleucher N, Metzner B, Schleicher J, Kanz L. (2002) Treatment-induced anaemia and ist potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87 (10): 1066–1071

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Bokemeyer C, Schmoll HJ, Polivoda H (1994) Sekundäre Leukämien nach Etoposid-haltiger Chamotherapie. Dtsch Med Wochenschr 119: 707–713

    Article  CAS  PubMed  Google Scholar 

  • Bowyer GW, Davies TW (1987) Methotrexate toxicity associated with an ileal conduit. Br J Urol 60: 592

    Article  CAS  PubMed  Google Scholar 

  • Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Hassison D (1978) Early anthracycline cardiotoxicity. Am J Med 65: 823–832

    Article  CAS  PubMed  Google Scholar 

  • Bronchud MH, Scarffe JH, Thatcher N (1988) Phase I/II study of recombinant human granulocyte colonystimulating factor in patients receiving intensive chemotherapy for small cell lung cancer recombinant human granulocyte-macrophage colonystimulating factor in AIDS (letter). N Eng J Med 318: 579

    Article  Google Scholar 

  • Bronner A, Hood A (1983) Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 9: 646–666

    Article  Google Scholar 

  • Canon JL (2005) Final Results of a Randomized, Double-Blind, Active-Controlled Trial of Darbepoetin alfa Administered Once Every 3 Weeks (Q3 W) for the Treatment of Anemia in Patients Receiving Multicycle Chemotherapy. Proc ASCO 23: 8284

    Google Scholar 

  • Carmichael DJS (1992) Handling of drugs in kidney disease. In: Cameron S, Davison AM, Grünfeld JP, Kerr D, Ritz E (eds) Oxford textbook of clinical nephrology. Univ Press Oxford, pp 175–196

    Google Scholar 

  • Cooper JAD Jr, White DA, Matthay RA (1986) Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 133: 321–340

    CAS  PubMed  Google Scholar 

  • De Bono JS (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (9747): 1147–1154

    Article  CAS  PubMed  Google Scholar 

  • De Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oral NK1 antagonist aprpitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21(22): 4105–11

    Article  CAS  PubMed  Google Scholar 

  • Di Lorenzo G, Autorino R, DArmiento FP, Mignogna C, De Laurentiis M, De Sio M, Darmiento M, Damiano R, Vecchio G, De Placido S (2004) Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 30(9): 987–92

    Article  CAS  PubMed  Google Scholar 

  • Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, DArmiento M, Bianco AR, De Placido S (2004) HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 90(2): 163–70

    CAS  PubMed  Google Scholar 

  • Drasga RE, Einhorn LH, Williams SD, Patel DN, Stevens EE (1983) Fertility after chemotherapy for testicular cancer. J Clin Oncol 1: 179–183

    CAS  PubMed  Google Scholar 

  • Du XX, Williams DA (1994) Interleukin 11: a multifunctional growth factor derived from the hematopoitic microenvironment. Blood 83: 2023–2030

    CAS  PubMed  Google Scholar 

  • Fink U, Peters HD, Schmoll HJ (1987) Antiemetische Therapie. In: Schmoll H-J, Peter H-D, Fink U (Hrsg) Kompendium internistische Onkologie. Springer, Berlin Heidelberg New York Tokyo, S 317–345

    Google Scholar 

  • Fossa SD, Ous S, Abyholm T, Norman N, Loeb M (1985) Post-treatment fertility in patients with testicular cancer. II. Influence of cis-platin-based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol 57: 210–214

    Article  CAS  PubMed  Google Scholar 

  • Fossa SD, Heilo A, Botinger O (1990) Unexpected high serum levels in cystectomiced bladder cancer patients with an ileals conduit treated intermediate doses of the drug. J Urol 143: 498

    CAS  PubMed  Google Scholar 

  • Gabrilove JL, Jakukowski A, Scher H (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell-carcinoma of the urothelium. N Engl J Med 318: 1414

    Article  CAS  PubMed  Google Scholar 

  • Gallmeier WM (1979) Zytostatikum para: was tun? Münch Med Wochenschr 121: 11

    CAS  Google Scholar 

  • Golde DW (1990) Hämatopoetine gleichen Abwehrschwäche aus. Oncol Rev 5/2: 6

    Google Scholar 

  • Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group (2003) The oral neurokin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin– the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22): 4112–4119

    Article  CAS  PubMed  Google Scholar 

  • Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8): 1074–80

    Article  CAS  PubMed  Google Scholar 

  • Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, Chinnaiyan AM, Rubin MA (2004) Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 6(5): 503–12

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ignoffo RJ, Friedman A (1980) Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17

    Article  CAS  PubMed  Google Scholar 

  • Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 9: 103–130

    CAS  PubMed  Google Scholar 

  • Köstering H, Nagel G (1982) Prophylaxe und Therapie von Zystostatika-Hautnekrosen. Onkologie: 3: 317

    Google Scholar 

  • Krege S (2003) Chemotherapy of advanced urological tumors. Onkologie Suppl 4: 13–7

    Article  Google Scholar 

  • Kreisman H, Wolkove N (1992) Pulmonary toxicity of antineiplastic therapy. In: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, pp 598–619

    Google Scholar 

  • Kuderer et al. (2005) Meta-analysis of prophylactic granulocyte-colony-stimulating-factor (G-CSF) in cancer patients receiving chemotherapy. Proc ASCO 2005; 23: #8117 Abstract

    Google Scholar 

  • La Bianca R, Beratta, Cleric M et al. (1982) Cardiac toxicity of 5-fluorouracil: a study of 1083 patients. Tumori 68: 505–510

    CAS  Google Scholar 

  • Lara PN Jr, Twardowski P, Quinn DI (2004) Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 3 (3): 165–173

    Article  CAS  PubMed  Google Scholar 

  • Larson DL (1982) Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796

    Article  CAS  PubMed  Google Scholar 

  • Leyden M, Sullivan J (1983) Full-Sickness skin-necrosis due to inadvertent interstitiell infusion of cis-platin. Cancer Treal Rep 67: 199

    CAS  Google Scholar 

  • Miller RS, Freiha FS, Torti FM (1991) Surgical restaging of PTS with advanced TCC of the urothelium treated with CHV. Proc ASCO 10: 530

    Google Scholar 

  • National Cancer Institute (NCI) (1993) Investigator’s handbook. A manual for participants in clinical trials of investigational agents. Cancer therapy evaluation program. Diversion of cancer treatment. National Cancer Institute, Bethesda/MD

    Google Scholar 

  • Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH (1993) Secondary leukemia associated with a conventional dose of etoposide. J Natl Cancer Inst 85: 36–40

    Article  CAS  PubMed  Google Scholar 

  • Perez CA, Brady LW (1993) Principles and practice of radiation oncology, 2nd edn. Lippincott, Philadelphia, pp 51–55

    Google Scholar 

  • Petersen PM, Hansen SW, Giwercman A, Rorth M, Stakkebaek NE (1994) Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 5: 355–358

    CAS  PubMed  Google Scholar 

  • Pizzo PA (1984) Granulocytopenia and cancer therapy. cancer 54: 2649

    Article  CAS  PubMed  Google Scholar 

  • Platzer E (1990) Human haemotopoetic growth factors. Eur J Haematol 42: 1

    Article  Google Scholar 

  • Pogothesis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU (1990) Excalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosyleted recombinant human granulocyte macrophage colony-stimulating factor. J Natl Cancer Inst 828: 667

    Google Scholar 

  • Pont J, Albrecht W (1997) Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 68: 1–5

    Article  CAS  PubMed  Google Scholar 

  • Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostata cancer. Prostate 62 (2): 115–22

    Article  CAS  PubMed  Google Scholar 

  • Rizzo JD, Lichtin AE, Woolf SH (2002) Use of Epoetin in patients with cancer: evidence-based clinical practice guidelines of American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 1–25

    Article  Google Scholar 

  • Roberts JT, Fossa SD, Parmar MKB (1991) Results of medical research council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced transitional cell carcinoma of the bladder. Br J Urol 68: 162

    Article  CAS  PubMed  Google Scholar 

  • Rosenow III EC, Meyers JL, Swensen SJ, Pisani RJ (1992) Drug-induced pulmonary disease- an update. Chest 102: 239–250

    Article  PubMed  Google Scholar 

  • Sauer H (2000) In: Wilmanns W, Huhn D, Wilms K (Hrsg) Internistische Onkologie. Thieme, Stuttgart New York

    Google Scholar 

  • Schaaf D, Schott E (1984) Entsorgung und Vernichtung von Zytostatikaabfällen. Krankenhauspharmazie 5. Jahrgang, Heft 10

    Google Scholar 

  • Schmoll HJ, Höffken K, Possinger K (1996) Kompendium Internistische Onkologie, Teil 1. 2. Aufl. Springer, Berlin Heidelberg New York Tokio

    Book  Google Scholar 

  • Sternberg CN, Yagoda A, Scher HI et al. (1986) Surgical staging and long term survival in patients with advanced transitional cell carcinoma (TCC) of the urothelium treated with M-VAC. Proc ASCO 5: 390

    Google Scholar 

  • Thurber WA (1989) Offspring of childhood cancer survivors. J Assoc Pediatr Oncol Nurses 6: 17–19

    Article  CAS  PubMed  Google Scholar 

  • Van Sloten Harwood K, Aisner J (1984) Treatment of chemotherapy extravasation: Current status. Cancer Treat Rep 68: 939

    Google Scholar 

  • Wander HE, Nagel GA (1985) Mammakarzinome, 3. Aufl. Zuckschwerdt, München Bern Wien

    Google Scholar 

  • Wood AJJ (1998) Drug therapy. N Engl J Med 339: 746–754

    Article  Google Scholar 

  • World Health Organisation (1979) WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva, Retrieved July 2004

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Westdeutsches Tumorzentrum, Innere Klinik (Tumorforschung), Universitätsklinikum Essen, Hufelandstraße 55, D-45122, Essen, Deutschland

    M. Schuler, J. Meiler & T. Gauler

  2. Urologie am Stern, Rüttenscheider Stern 5, D-45130, Essen, Deutschland

    T. Jäger

  3. Klinik für Urologie und Kinderurologie, Alexianer Krefeld GmbH, Krankenhaus Maria Hilf, Dießemer Bruch 81, D-47805, Krefeld, Deutschland

    S. Krege

  4. Klinik und Poliklinik für Urologie, Universitätsklinikum Essen, Hufelandstraße 55, D-45122, Essen, Deutschland

    H. Rübben

Authors
  1. M. Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Meiler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Gauler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Urologie, Universitätsklinikum Essen, Essen, Germany

    Herbert Rübben

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schuler, M., Jäger, T., Meiler, J., Gauler, T., Krege, S., Rübben, H. (2014). Grundlagen der systemischen Therapie. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35032-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35032-0_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35031-3

  • Online ISBN: 978-3-642-35032-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation